Cargando…
The role of acalabrutinib in adults with chronic lymphocytic leukemia
The treatment landscape of chronic lymphocytic leukemia (CLL) has significantly changed in the past decade. This paradigm shift is due to the introduction of novel agents to the field. The two major classes of drugs that have contributed to this dramatic evolution include the Bruton tyrosine kinase...
Autores principales: | Fakhri, Bita, Andreadis, Charalambos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871059/ https://www.ncbi.nlm.nih.gov/pubmed/33613932 http://dx.doi.org/10.1177/2040620721990553 |
Ejemplares similares
-
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021) -
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021) -
Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023) -
Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia
por: Lütge, Almut, et al.
Publicado: (2023) -
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)